Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer's drug for approval
07:27pm, Friday, 09'th Jun 2023
Biogen Inc. BIIB, +1.31% shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and Drug Administration advisory c
Here's what the FDA's endorsement of the Alzheimer's drug Leqembi means for Biogen
05:33pm, Friday, 09'th Jun 2023
Matt Herper, Stat News senior writer, joins 'Closing Bell: Overtime' to discuss the FDA advisers' unanimous vote to recommend Biogen Alzheimer's drug.
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
02:29pm, Friday, 09'th Jun 2023
Biogen stock was halted Friday as a panel of experts to the FDA debated the merits of its Alzheimer's treatment, Leqembi.
FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval
10:07am, Friday, 09'th Jun 2023
Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment.
FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen
07:04am, Friday, 09'th Jun 2023
A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for
Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod
01:53pm, Thursday, 08'th Jun 2023
Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.
Mastering the Double-Bottom Pattern (Unveiling 3 Intriguing Setups in Today's Market)
07:20pm, Wednesday, 07'th Jun 2023
A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils
Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122
11:59am, Tuesday, 06'th Jun 2023
Biogen BIIB announced that it is discontinuing one of the two studies on its and partner Denali Therapeutics' DNLI small molecule LRRK2 inhibitor, BIIB122, for Parkinson's disease.
Medicare unveils plan for coverage of new Alzheimer's drugs
01:44pm, Thursday, 01'st Jun 2023
Medicare on Thursday announced plans for coverage of new Alzheimer's drugs whose accessibility has become a point of controversy.
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
12:17pm, Thursday, 01'st Jun 2023
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.
Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?
12:32pm, Thursday, 25'th May 2023
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
10:00am, Friday, 19'th May 2023
The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
08:15am, Friday, 19'th May 2023
Biogen and Eli Lilly both have promising Alzheimer's drugs that have shown they are effective in slowing the rate of cognitive decline in patients. They both come with risks related to brain swelling
Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on
07:27pm, Monday, 15'th May 2023
CNBC's Jim Cramer is looking to 2011 for investing guidance during the ongoing debt ceiling uncertainty.
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
08:15am, Sunday, 14'th May 2023
Two new medicines are going to compete for the Alzheimer's therapy market. Eli Lilly's candidate appears to be more effective, but it isn't approved yet.
